ESMO 2019 preview – PARPs on parade

With this weekend’s World Lung meeting still fresh in the mind oncology watchers will have no time to rest on their laurels. The next major conference, Esmo, is set to kick off just two weeks later, and it even takes place at the same venue in Barcelona.

True to recent form Esmo is continuing to make a push to outclass Asco as the world’s most important cancer meeting, something that largely depends on the timing of study readouts. All the abstract titles are now out, revealing late-breaker slots for numerous trials toplined in recent weeks, perhaps the most important of which is the Paola-1 study of Astrazeneca’s Parp inhibitor, Lynparza.